Human Albumin ”CSL Behring”

DRUG2 trials

Sponsors

CSL Behring LLC, Rigshospitalet

Conditions

Acute critical illness requiring intensive care unit admission.Post-COVID-19 Postural Orthostatic Tachycardia Syndrome

Phase 3

Double-blind, Randomized, Placebo-controlled Phase 3 study Evaluating Efficacy and Safety of IgPro20 (subcutaneous immunoglobulin, HIZENTRA®) in post-COVID-19 Postural Orthostatic Tachycardia Syndrome (POTS)

CompletedCTIS2023-508744-22-00

CSL Behring LLCPost-COVID-19 Postural Orthostatic Tachycardia Syndrome

End: 2025-05-13Target: 17Updated: 2025-05-08

Phase 4

The Intensive Care Platform Trial (INCEPT)

RecruitingCTIS2024-516208-41-00

RigshospitaletAcute critical illness requiring intensive care unit admission.

Start: 2025-06-26Target: 20000Updated: 2025-12-22